Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of RUCONEST comparison with a competitor product for the treatment of acute attacks of hereditary angioedema

Trial Profile

A clinical study of RUCONEST comparison with a competitor product for the treatment of acute attacks of hereditary angioedema

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2018 New trial record
    • 25 Jul 2018 According to a media release, patient recruitment in this study is expected to be completed in Q3. The top-line data is expected in Q4 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top